Ajinomoto Althea & AltheaDx

The requested name combines two distinct acquired healthcare companies: Ajinomoto Althea, a San Diego sterile fill-finish CDMO, and AltheaDx, a molecular diagnostics and pharmacogenomics company. Ajinomoto Althea was established as Ajinomoto Althea, Inc., operated as a member of Ajinomoto Bio-Pharma Services, and provided formulation plus aseptic fill-finish services for clinical- and commercial-stage biopharmaceutical products, especially injectable drug products such as prefilled syringes and cartridges. Ajinomoto signed an agreement to sell Ajinomoto Althea to PCI Pharma Services on April 24, 2025, and the transaction was completed on May 1, 2025. Separately, AltheaDx developed and commercialized IDgenetix, a pharmacogenomic test intended to guide medication selection for mental health conditions, and was acquired by Castle Biosciences in April 2022. Because the user-provided name merges two separate entities, this record prioritizes Ajinomoto Althea as the canonical match while capturing AltheaDx as a related but distinct company name.